Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04359680 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
A Phase 3 study, sponsored by Romark Laboratories L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 1,407
- Enrollment target
NCT04359680 is a Phase 3 study that has completed, run by Romark Laboratories L.C.. The registered enrollment target is 1,407 participants.
The verdict
NCT04359680, a Phase 3 study, has completed, sponsored by Romark Laboratories L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,407 participants
- Enrollment target
Study Summary
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Interventions
- DRUG Placebo
- DRUG Nitazoxanide
- DIETARY_SUPPLEMENT Vitamin Super B-Complex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,407 participants |
| Start Date | 2020-05-13 |
| Est. Completion | 2021-04-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04359680
The ClinicalTrials.gov registry entry for NCT04359680 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,407 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Romark Laboratories L.C., which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04359680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04359680 about?
NCT04359680 is a clinical study titled "Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection". Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
What is the current status of trial NCT04359680?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,407 participants. The study started on 2020-05-13. Estimated completion is 2021-04-07.
What interventions are being tested in trial NCT04359680?
The interventions under investigation include: Placebo (DRUG), Nitazoxanide (DRUG), Vitamin Super B-Complex (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04359680?
This trial is sponsored by Romark Laboratories L.C., which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.